AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01199029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Study NCT01199029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
Study NCT01199029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
Study NCT01199029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Study NCT02761304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT02761304 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Study NCT01973777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUB
Description: intrauterine contraceptive device
Study NCT00689468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial osteopathic manipulative treatment.
Description: A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).
Study NCT00689468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea
Description: 1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
Study NCT00689468 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham osteopathic manipulative treatment
Description: Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
Study NCT00689468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham osteopathic manipulative treatment
Description: Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
Study NCT00689468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Echinacea purpurea placebo
Description: An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
Study NCT00689468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea placebo
Description: An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
Study NCT01183143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GONAL-f®
Description: GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
Study NCT00307151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 4 mg/kg twice daily
Study NCT00307151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: 16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg
Study NCT00307151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m\^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m\^2/dose to max 200 mg twice daily
Study NCT00307151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: 180 mg/m\^2 twice daily
Study NCT01469338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: Given IV
Study NCT01469338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT01469338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide pamoate
Description: Given IM
Study NCT01469338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01469338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Description: Given SC
Study NCT02756728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-505
Description: Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months
Study NCT02756728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dose melphalan
Description: High dose melphalan (HDM)
Study NCT02756728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High dose melphalan
Description: High dose melphalan (HDM)
Study NCT02756728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Description: Autologous stem cell transplantation (ASCT)
Study NCT02756728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous stem cell transplantation
Description: Autologous stem cell transplantation (ASCT)
Study NCT01653288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Coach
Description: Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
Study NCT00950508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High volume plasma exchange
Description: 3 high volume plasma exchanges over 3 days
Study NCT00950508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment
Study NCT00950508 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment
Study NCT04350853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical extrusion
Description: Surgically coronal reposition of the tooth
Study NCT01221064 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early drainage removal
Description: Drainage will be removed in postoperative day 1
Study NCT01221064 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Late drainage removal
Description: Drains will be kept until daily drainage is 30ml and then removed
Study NCT00897663 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Study NCT00897663 — intervention group
Intervention type: GENETIC
Intervention: microarray analysis
Study NCT00897663 — intervention group
Intervention type: GENETIC
Intervention: protein expression analysis
Study NCT00897663 — intervention group
Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study NCT00897663 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry staining method
Study NCT01388673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy
Description: The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
Study NCT04395339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialotetrahexosyl ganglioside (GM1)
Description: Ganglioside-Monosialic Acid is added into 250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
Study NCT04395339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
Study NCT02982954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day
Study NCT02982954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified Dose on Specified Day
Study NCT03435848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BST-236
Description: 1 to 4 courses
Study NCT02807480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based therapy
Description: Exposure-based therapy
Study NCT02807480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation therapy
Description: Behavioral Activation therapy
Study NCT02807480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based behavioral assessment
Description: Computer-based tasks during which participants respond to images on the screen, including abstract images, emotional faces, and pleasant and unpleasant images.
Study NCT02807480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys and Interviews
Description: Surveys and interviews in which participants will be asked to answer questions related to their mental and physical health history and current symptoms.
Study NCT02807480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Magnetic resonance imaging (MRI) will be used to obtain information concerning the structure of the brain, as well as to assess changes associated with blood flow in the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
Study NCT02807480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) will be used to assess changes in the electrical activity of the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
Study NCT04467424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine, propofol
Description: anesthesia with ketofol in pediatric surgery
Study NCT04467424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine, propofol, lidocaine
Description: anesthesia with ketofol plus lidocaine in pediatric surgery
Study NCT00176605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
Study NCT00176605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
Study NCT04272684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving Assessment
Description: Participants will undergo a driving assessment approximately two months after returning home from hospital
Study NCT01321710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Description: This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy.
Study NCT01321710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary information
Description: This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
Study NCT01321710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
Study NCT03709238 — intervention group
Intervention type: BEHAVIORAL
Intervention: Thermal stimulation
Description: Thermal stimulation
Study NCT01227187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa activated (Xigris)
Description: We will test different dose regimens of Drotrecogin alfa activated (Xigris) to determine the optimal dose to achieve PTT between 65 and 100 secs. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via pre-filter arterial drip chamber via a standard IV pump. The PTT will be assessed at baseline,15,30,60,120 and 180 mins. Xigris dose will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains \<65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
Study NCT01097746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01097746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01097746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02829307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-GSK3128349 1 mg
Description: 89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
Study NCT03670212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine Hydrochloride
Description: 54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.
Study NCT03670212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
Study NCT03670212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Monohydrate Powder
Description: Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
Study NCT03553043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Energy label condition.
Study NCT03553043 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No label
Study NCT00350051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (ZK 219477) + prednisone
Description: Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
Study NCT03269071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human fetal-derived Neural Stem Cells (hNSCs)
Description: The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture.
Study NCT04117464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation therapy
Description: Behavioral activation therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
Study NCT04117464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
Study NCT04117464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Cognitive-Behavioral Therapy on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
Study NCT04117464 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait List Group
Description: No psychological intervention
Study NCT03113500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT03113500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03113500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT03113500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03113500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03113500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study NCT03113500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03113500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02732769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GammaKnifePerfexion®
Description: neurosurgery
Study NCT02732769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaKnifeIcon®
Description: neurosurgery
Study NCT02732769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efficast®
Description: Thermoformed mask
Study NCT02732769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Study NCT02732769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT04066582 — intervention group
Intervention type: DEVICE
Intervention: ApolloVue™ S100 image system, Viper1-S003
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
Study NCT01652183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous paracetamol
Study NCT01652183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02034890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
Study NCT02363140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Will undergo a single MRI assessment with intravenous dye
Study NCT02363140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pre and post surgery MRI scan
Study NCT03687151 — intervention group
Intervention type: OTHER
Intervention: non intervention / observationnal
Description: non intervention / observationnal
Study NCT01692964 — intervention group
Intervention type: DEVICE
Intervention: InflammaDry
Description: A noninvasive immunoassay for detecting MMP-9 levels in tears.
Study NCT03825874 — intervention group
Intervention type: OTHER
Intervention: Amikacin
Description: A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.